Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced today the pricing of a registered underwritten public offering of 3,571,429 shares of its common stock at a public offering price of $7.00 per share pursuant to a shelf registration statement that was previously filed with and declared effective by the Securities and Exchange Commission (SEC). All of the shares in the offering are to be sold by the Company.
Cantor Fitzgerald & Co. is acting as the sole bookrunner for the offering.
The offering is expected to close on or about January 27, 2017, subject to customary closing conditions.
Before investing in the offering, interested parties may read the prospectus supplement and the accompanying prospectus for the offering and the other documents the Company has filed with the SEC, which are incorporated by reference in the prospectus supplement and the accompanying prospectus for the offering and provide more complete information about the Company and the offering. An electronic copy of the prospectus supplement and the accompanying prospectus for the offering will be available on the website of the SEC at www.sec.gov. Copies of the final prospectus supplement, when available, and the accompanying prospectus relating to this offering may be obtained by contacting Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Ave., 5th Floor, New York, New York 10022, or by telephone at 212-829-7122, or by e-mail at prospectus@cantor.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction. Offers will be made only by means of a prospectus supplement and the accompanying prospectus, forming a part of the registration statement.
About Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix has resubmitted a new drug application (NDA) for post-surgical pain for its lead product candidate, DEXTENZA, which has completed Phase 3 clinical development for post-surgical ocular inflammation and pain. Subject to the approval of the NDA for post-surgical ocular pain, Ocular Therapeutix intends to submit a supplemental NDA for DEXTENZA to broaden its label to include an indication for post-surgical inflammation. DEXTENZA is also in Phase 3 clinical development for allergic conjunctivitis. OTX-TP is in Phase 3 clinical development for glaucoma and ocular hypertension. Ocular Therapeutix is also evaluating injectable drug delivery depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company including the development and regulatory status of the Company's product candidates, such as the Company's expectations and plans regarding regulatory submissions for and the timing and conduct of clinical trials of DEXTENZA for the treatment of post-surgical ocular inflammation and pain, including the Company's expectations regarding the NDA filed with the FDA and the resubmission of the NDA, DEXTENZA for the treatment of allergic conjunctivitis and OTX-TP for the treatment of glaucoma and ocular hypertension, the ongoing development of the Company's injectable drug delivery depots for back-of-the-eye diseases, the potential utility of any of the Company's product candidates, the potential commercialization of the Company's product candidates, the Company's expectations related to the offering discussed in this press release and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "goal," "may," "might," "plan," "predict," "project," "target," "potential," "will," "...
expresspharma January 11, 2021
cphi-online January 18, 2017
cphi-online January 18, 2017
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
(All Rights Reserved)
(All Rights Reserved)